

Attorney Docket No.: DEX0489US.NP
Inventors: Duan et al.
Serial No.: 10/558,543
Filing Date: October 23, 2006
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1-19 (canceled)

Claim 20 (currently amended): A kit ~~for diagnosing a patient's susceptibility to prostate cancer or ovarian cancer~~ comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring CA125 levels ~~wherein the levels of Cln101 are determined.~~

Claim 21-23 (canceled)

Claim 24 (currently amended): ~~An isolated Cln101 antibody that~~ The antibody of claim 30 which binds to mammalian Cln101 in vivo or in vitro.

Claim 25 (currently amended): The antibody of ~~claim 24~~ claim 30 which internalizes upon binding to Cln101 on a mammalian cell in vivo.

Claim 26 (currently amended): The antibody of ~~claim 24~~ claim 30 which is a monoclonal antibody, an antibody fragment or a chimeric or a humanized antibody.

Claims 27-28 (canceled)

Claim 29 (original): The antibody of claim 26 which is produced by a hybridoma selected from the group consisting

Attorney Docket No.: **DEX0489US.NP**
Inventors: **Duan et al.**
Serial No.: **10/558,543**
Filing Date: **October 23, 2006**
Page 4

of American Type Culture Collection accession number PTA-5877 and PTA-5876.

Claim 30 (currently amended): ~~The antibody of claim 24, wherein the~~ An isolated antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876.

Claim 31 (currently amended): The antibody of ~~claim 24~~ claim 30 which is conjugated to a growth inhibitory agent or a cytotoxic agent.

Claim 32-44 (canceled)

Claim 45 (currently amended): ~~A cell~~ An isolated cell that produces the antibody of claim 26.

Claim 46 (original): The cell of claim 45, wherein the cell is selected from the group consisting of hybridoma cells deposited under American Type Culture Collection accession number PTA-5877 and PTA-5876.

Claim 47 (canceled)

Claim 48 (currently amended): A composition comprising the antibody of ~~claim 24~~ claim 30, and a carrier.

Claim 49-50 (canceled)

Attorney Docket No.: **DEX0489US.NP**
Inventors: **Duan et al.**
Serial No.: **10/558,543**
Filing Date: **October 23, 2006**
Page 5

Claim 51 (original): The composition of claim 48, wherein the antibody is a human or humanized antibody and the carrier is a pharmaceutical carrier.

Claim 52-94 (canceled)

Claim 95 (currently amended): ~~The kit of claim 20 for diagnosing a patient's susceptibility to prostate cancer further~~ A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the levels of both PSA and Cln101 are determined assay for Cln101 comprises the antibodies of claim 30.

Claim 96 (new): The antibody of claim 30 which is detectably labeled.

Claim 97 (new): The antibody of claim 96 wherein the label is selected from the group comprising radioisotope, fluorescent, enzymatic, biotin, and gold particle labels.